Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant in Pediatric Fragile X Syndrome
NCT01750957Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of basimglurant in Fragile X syndrome (FXS) (3 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events at 15 weeks. Started Feb 2013; status: completed.
02
Drugs
basimglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01750957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750957.